focus -WSS

focus

author：Wikipedia 2025-08-23 22:02:01 - browse：94

Blood samples — Marion Berard/AFP/GettyImages

With the advent of disease-modifying Alzheimer’s drugs, everyone in the world of Alzheimer’s diagnostics is bracing for the crush.

Based on their ability to slow cognitive decline, the Eisai/Biogen drug Leqembi won full approval from the FDA this month, and donanemab by Eli Lilly could be approved by year end. Clinicians now have to decide which patients are most suitable for treatment, which means better Alzheimer’s tests need to be developed.

“There’s going to be capacity issues because there’s just not enough neurologists in the world to treat this pool of patients with Alzheimer’s disease at the moment,” said Mark Stearman, a senior international product manager at Roche focusing on Alzheimer’s diagnostics.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How one medical school became remarkably diverse
Next article： Mega Millions jackpot rises to record $1.55 billion for Tuesday's drawing

focus

WSS

2 US Navy sailors arrested for allegedly spying for China

Attacks on the drug industry will lead to fewer breakthroughs

Listen: PBM conflicts, RSV vaccines, & the future of flu season

A cyberattack has disrupted hospitals and health care in several states

Stem cell clinics for heart failure: buyer be wary

Verily hires former Apple Health leader as chief scientific officer

hotspot

focus

hotspot

DIEP, the 'gold standard' of breast reconstruction, is under threat

Dramatically reducing cancer deaths requires the PASTEUR Act

Heart attack and stroke risk calculators need revising

Wild otter attack leads to woman being airlifted to hospital, 2 others treated for injuries

Medical leaders decry Supreme Court decision on affirmative action

4 killed, 7 hurt in mass shooting at July 4 block party in Louisiana; no arrests made

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

New case study details death in closely watched Alzhiemer's trial

Moonlake's readout produced a cash windfall. Risks remain

Pfizer's Covid pill remains 89% effective in final analysis, company says

hotspot

Option Care buys Amedisys in $3.6 billion home care deal

Treeline, Josh Bilenker's next biotech, is cloaked in mystery

Doctor appointment wait times are getting worse

CDC: Uninsured rate hit 'record low' right as states cut Medicaid

Connecting traumatic brain injury and domestic violence

Why is France rioting? What to know about the fatal police shooting of Nahel M

focus

leisure time

focus

entertainment